Safety and Efficacy of Lidocaine Prilocaine Spray in Reducing Pain During Hysterosalpingography in Women With Primary Infertility

Cairo University0 sites90 target enrollmentFebruary 10, 2025

ConditionsInfertility, Female

InterventionsEMLA SPRAY Placebo

DrugsEMLA SPRAY Placebo

Overview

Phase: Phase 3
Intervention: EMLA SPRAY
Conditions: Infertility, Female
Sponsor: Cairo University
Enrollment: 90
Primary Endpoint: pain during Cervical instrumentation of the tenaculum and cannula
Status: Not yet recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

We aim to assess the Safety and Efficacy of Cervical Lidocaine Prilocaine Spray in Reducing Pain During Hysterosalpingography in women with primary infertility

Detailed Description

We aim to assess the Safety and Efficacy of Cervical Lidocaine Prilocaine Spray in Reducing Pain During Hysterosalpingography in Women with Primary Infertility.

Registry

clinicaltrials.gov

Start Date

February 10, 2025

End Date

August 15, 2025

Last Updated

last year

Study Type

Interventional

Study Design

Parallel

Sex

Female

Investigators

Sponsor

Cairo University

Responsible Party

Principal Investigator

Ahmed Samy aly ashour

professor

Cairo University

Eligibility Criteria

Inclusion Criteria

•Women aged 18-45 years. Diagnosed with primary infertility (no prior pregnancy after at least 12 months of unprotected intercourse) and scheduled for HSG as part of infertility evaluation.

Exclusion Criteria

•Known allergy or hypersensitivity to lidocaine, prilocaine, or any components of the spray.
•Current pregnancy or suspicion of pregnancy.
•Active pelvic inflammatory disease or history of severe pelvic infections within the last 6 months.
•Use of systemic analgesics, sedatives, or anesthetics within 24 hours prior to the procedure.